Navigation Links
AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Date:11/24/2009

    Primary efficacy endpoint has been met for patients with advanced-stage
    or recurrent endometrial cancer

QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer. In a personalized health care approach, the study selected patients with tumors expressing luteinizing hormone-releasing hormone (LHRH) receptors, the key element in the targeting mechanism of AEZS-108. Under the coordination of Prof. Gunter Emons, MD, Chairman of the Department of Obstetrics & Gynaecology at the University of Gottingen, Germany, this open-label, multi-center and multi-national Phase 2 study AGO-GYN 5, is being conducted by the German AGO Study Group (Arbeitsgemeinschaft Gynakologische Onkologie/Gynaecological Oncology Working Group; www.ago-ovar.de), in cooperation with clinical sites in Europe.

Preliminary Results

A preliminary evaluation has shown that the study AGO-GYN 5 met its predefined primary efficacy endpoint of 5 or more responder patients with endometrial cancer. The study is currently ongoing, and responders, as well as patients with stable disease after completion of treatment with AEZS-108, will be followed to assess the duration of progression-free survival and, ultimately, overall survival. Detailed analyses of the study results will be presented at forthcoming scientific conferences.

Juergen Engel, Ph.D., President and Chief Executive Officer at AEterna Zentaris stated, "We are pleased with the progress of this Ph
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that executives from ... the month of September.  , ... Rodman & Renshaw,s 17th Annual Global Investment Conference on ... the St. Regis Hotel in New York ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Inc. Magazine ... States, ranking iLab Solutions as number 1,361 in growth for the three years through ... the top 0.1% fastest-growing privately held organizations in the country. , “We are ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... PRINCETON, N.J., July 16 BioWa, Inc. ... today that they have entered into a,license ... ever access to,BioWa,s COMPLEGENT(TM) Technology for enhancing ... antibodies., The license grants Medarex non-exclusive ...
... July 16 U.S. Genomics today announced,the award ... Department of Homeland,Security (DHS) Science and Technology Directorate. ... Detectors (BAND) program will,enable U.S. Genomics to continue ... sensor for the detection of airborne,pathogens using single ...
... and LONDON and PRINCETON, New Jersey, July ... three years,from the original introduction of its ... 20,pharmaceutical companies have introduced and adopted the ... is a bench-top,standalone hydrogenation reactor, uniquely combining ...
Cached Biology Technology:BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology 2BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology 3BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology 4U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security 2World's Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc. 2
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... doesn,t stop at borders. Mexico, the U.S., and Canada ... and resource problems. In an effort to promote active ... of Geoscience and the Institute of Geology of the ... Mxico; UNAM) are hosting the 108th meeting of GSA,s ...
... two-thirds of the oil we use comes from wells ... nearly 30 years ago to lower the cost of ... the technology fullcircle, showing how geothermal drillers might use ... by the oil and gas industry. Sandia and ...
... of fluid into the intra- or extracellular spaces of ... such as stroke or head trauma, among others. ... in other organs swelling does not lead to an ... and death. Although there are therapeutic solutions such as ...
Cached Biology News:Geological Society of America Cordilleran section meets in the heart of Mexico 2Geological Society of America Cordilleran section meets in the heart of Mexico 3Geological Society of America Cordilleran section meets in the heart of Mexico 4Polycrystalline diamond drill bits open up options for geothermal energy 2Polycrystalline diamond drill bits open up options for geothermal energy 3Polycrystalline diamond drill bits open up options for geothermal energy 4Step forward in research into new treatments for brain edema 2
PKC (pSer345), phospho-specific...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
WD-repeat protein 4...
Biology Products: